12:00 AM
Mar 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

OvaRex: Continued Phase IIb trial

AltaRex Corp. (TSE:AXO), Waltham, Mass.
Product: OvaRex
Business: Cancer
Therapeutic category: Immune stimulation
Target: CA125 antigen
Description: Monoclonal antibody against CA125 that stimulates an anti-idiotype immune...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >